Trial Profile
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema; Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms Protocol-W
- 15 Aug 2022 Status changed from active, no longer recruiting to completed.
- 06 May 2021 According to a Regeneron Pharmaceuticals media release, initial results from this study were published in JAMA Ophthalmology in Mar 2021.
- 10 Feb 2020 Planned End Date changed from 1 Jan 2022 to 1 May 2022.